Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes

Chronic hyperglycaemia and glucose variability are associated with the development of chronic diabetes-related complications. We conducted a pooled analysis of patient-level data from three 24-week, randomized, phase III clinical trials to evaluate the impact of lixisenatide (LIXI) on glycaemic vari...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2017

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/23850

Acceso en línea:

https://doi.org/10.1111/dom.12930
https://repository.urosario.edu.co/handle/10336/23850

Palabra clave:

Glucose
Hemoglobin a1c
Insulin
Lixisenatide
Placebo
Antidiabetic agent
Glucagon like peptide 1 receptor
Glycosylated hemoglobin
Insulin
Lixisenatide
Peptide
Article
Body mass
Clinical effectiveness
Clinical evaluation
Disease duration
Drug efficacy
Endocrine function
Follow up
Glucose blood level
Glycemic variability
Hemoglobin blood level
Human
Hypoglycemia
Major clinical study
Multicenter study (topic)
Non insulin dependent diabetes mellitus
Phase 3 clinical trial (topic)
Randomized controlled trial (topic)
Agonists
Analysis
Blood
Blood glucose monitoring
Chemically induced
Clinical trial
Cohort analysis
Combination drug therapy
Controlled study
Double blind procedure
Drug resistance
Hyperglycemia
Hypoglycemia
Intention to treat analysis
Metabolism
Middle aged
Non insulin dependent diabetes mellitus
Pathophysiology
Phase 3 clinical trial
Randomized controlled trial
Reproducibility
Severity of illness index
Blood glucose
Blood glucose self-monitoring
Cohort studies
Double-blind method
Drug resistance
Follow-up studies
Glucagon-like peptide-1 receptor
Glycated hemoglobin a
Humans
Hyperglycemia
Hypoglycemia
Hypoglycemic agents
Insulin
Intention to treat analysis
Middle aged
Peptides
Reproducibility of results
Severity of illness index
Glycaemic variability
Insulin
Lixisenatide
Type 2 diabetes
type 2
combination
human
human
Glp1r protein
Hemoglobin a1c protein
Diabetes mellitus
Drug therapy

Rights

License

Abierto (Texto Completo)